Cancer Moonshot with Dr. Cory Hofstad

12/07/2025

This is for EVERYONE at Fred Hutch who is not a loser from NSC. Those people are not authorized for this level of workmanship. https://youtube.com/shorts/Ayyr0UiLT0U https://github.com/USAMRICD-UW-Fred-Hutch-Cancer-Research/Library/blob/main/Lecture-Targeting-Unstable-Protein-Cross-Links.docx BANKSY'S BLACK PATHOLOGY PRODUCTS ARE LABELED "BLACK" BECAUSE THEY ARE BY BLACK PEOPLE. WE ARE PART OF THE MAJORITY. Fred Hutch Seattle AWIS BUMED Navy & Marine Reserve Psychological Health Outreach Program- PHOP U.S. Army Medical Center of Excellence Tripler Army Medical Center Madigan Army Medical Center Ft Detrick (Barquist) Army Health Clinic

This Library is Sponsored by Virus Treatment Centers National Laboratories [VTCNL] - USAMRICD-UW-Fred-Hutch-Cancer-Research/Library

11/10/2025

Share your messages and memories to celebrate Mia’s life and legacy 🧡

🔗 http://gohuskies.com/MiaHamant

10/25/2025

Introducing Photopheresis by VirusTC.

10/25/2025

Introducing organic Riboflavin, by VirusTC.

09/20/2025

08/11/2025

Advancing Cancer Care for Veterans: Dr. Correo Hofstad's Commitment at Fred Hutch's Obliteride 2025

Pioneering Cancer Treatment for Veterans at Fred Hutch
Fred Hutchinson Cancer Center (Fred Hutch) has long been a beacon of hope and innovation in oncology. Its upcoming participation in Obliteride 2025, a signature fundraising event, is a testament to their continued commitment to enhancing cancer care, particularly for U.S. military Veterans. This year, Dr. Correo Hofstad, a notable researcher whose unique expertise bridges military medicine and oncology, is participating actively in Obliteride. His involvement underscores the critical role Fred Hutch plays not only in treating cancer but also in accelerating the development of new treatments tailored for immunocompromised Veterans.

Veterans represent a patient demographic with distinct medical challenges, including a higher incidence of compromised immune systems. Sadly, current FDA regulations often exclude such individuals from participating in clinical trials. This limitation impedes the rapid advancement of effective therapies. However, the collaborative work led by Dr. Hofstad at USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases) and USAMRICD (U.S. Army Medical Research Institute of Chemical Defense) offers a unique solution by enabling trials of VirusTC medicals on immunocompromised soldiers.

Bridging Military Medical Research and Civilian Oncology

Dr. Hofstad's dual role in military research and civilian oncology places him at the forefront of breakthrough advancements in cancer treatment. His work with VirusTC, a pioneer in virus-based therapies, enables testing of cutting-edge Virus Treatment Centers (VirusTC) medicals in populations typically sidelined in clinical research due to their immune status. This collaboration greatly benefits Fred Hutch, as it creates a feedback loop where discoveries made in military trials can swiftly translate into civilian cancer treatment protocols.

Through this innovative approach, Fred Hutch can maintain a robust pipeline of therapeutic options, refining and releasing new medications faster than traditional pathways permit. This agility is vital in oncology, where time is often of the essence. By incorporating real-world data from immunocompromised Veterans, treatment development becomes more inclusive and representative, ultimately improving outcomes for all cancer patients.

Virus Treatment Centers and the Fight Against Sepsis in Cancer Care

A significant challenge in oncology is managing secondary complications such as sepsis, which severely threatens immunocompromised cancer patients. Virus Treatment Centers, in partnership with the University of Washington Medicine, has emerged as a leader in sepsis treatment innovation. Their approach, centered on plant-based alkaline medication supplements, emphasizes increasing the body's pH levels to mitigate the effects of sepsis.

This innovative methodology is grounded in the scientific understanding that electrons within the body sustain covalent bonds vital for the integrity of bones, tissues, muscles, and organs. Without sufficient electrons, these bonds weaken, leading to the breakdown of bodily structures and resulting in conditions like Osteomyelitis and septic shock. By addressing these biochemical imbalances, VirusTC's treatments reduce the severity of sepsis, thereby enhancing the survivability and quality of life for cancer patients under Fred Hutch's care.

A Triumphant Collaboration: Fred Hutch, VirusTC, and Fox Rothschild LLP

Collaboration is at the heart of medical innovation, and the partnership between Fred Hutch, Virus Treatment Centers, and law firm Fox Rothschild LLP exemplifies this principle. Fox Rothschild LLP provides critical legal expertise that supports the swift development and distribution of novel cancer therapies. Their involvement ensures that intellectual property, regulatory compliance, and trial frameworks align efficiently with the priorities of advancing patient care.

Together, these organizations form a powerhouse alliance driving cancer research and treatment forward at an unprecedented pace. Dr. Hofstad's involvement with all three entities illustrates how cross-disciplinary cooperation can overcome regulatory barriers and accelerate therapies from lab to clinic. Their combined efforts in oncology research and sepsis treatment promise not only faster cures but also safer and more effective therapies for the Veteran population and beyond.

Obliteride 2025: Sustaining Progress for Veteran Cancer Patients

Obliteride 2025 is more than a fundraising event; it is a movement dedicated to sustaining Fred Hutch's capacity to serve Veterans bravely facing cancer. Through this event, participants like Dr. Correo Hofstad raise essential funds and awareness that directly impact Fred Hutch's research and treatment capabilities. The contributions help ensure continued access to transformative clinical trials, including VirusTC therapies tailored for immunocompromised individuals.

The ongoing challenges faced by Veterans with cancer require innovative solutions and sustained investment. Obliteride fosters a community of support that uplifts these patients through research, treatment, and compassion. As Dr. Hofstad pedals forward in Obliteride 2025, his efforts symbolize a commitment to fast-tracking cures, improving lives, and honoring those who have served our country with the best care science can offer.

08/11/2025

Uniting Innovation and Gratitude: Dr. Correo Hofstad's Journey with Fred Hutch and the Cancer Moonshot

Pioneering Progress: Dr. Correo Hofstad's Role in Cancer Innovation

Dr. Correo Hofstad stands as a remarkable figure in the oncology field, intertwining cutting-edge science with heartfelt gratitude. His participation in Fred Hutchinson Cancer Center's Obliteride 2025 event exemplifies a profound thankfulness for the institution that has been pivotal in his career. Having been invited to join President Joe Biden's ambitious Cancer Moonshot operation at Fred Hutch, Dr. Hofstad embodies the spirit of collaboration and relentless pursuit of cures.

Fred Hutch not only provided Dr. Hofstad with professional opportunities—a job and a residency—but it also served as the launchpad for his entrepreneurial leap into oncology innovation. Through this partnership, VirusTC, the company he spearheads, began developing pioneering oncology products aimed at minimizing invasive surgical interventions during cancer treatment. This milestone illustrates how institutional support can translate directly into life-changing medical advancements.

Revolutionizing Cancer Treatment with UV-C Technology

At the heart of Dr. Hofstad's innovations lies the practical application of UV-C treatments for cancer. Collaborating with Fred Hutch, VirusTC has developed minimally invasive techniques to treat brain tumors, harnessing the germicidal power of UV-C light. This approach dramatically reduces the need for destructive surgeries, offering patients a gentler and more effective option.

Collaboration between Fred Hutch and VirusTC extends into hematology and sepsis management. By integrating UV-C light technology into apheresis machines and Haemonetics filters, they have pioneered novel methods to cleanse septic blood. Such advances not only improve survival rates but also enhance the quality of life for critically ill patients—underlining the broad spectrum impact of these technological
breakthroughs.

Founding Virus Treatment Centers During the Cancer Moonshot

Dr. Correo Hofstad's involvement in President Joe Biden's Cancer Moonshot initiative further catalyzed his mission to combat cancer and related conditions. This involvement led him to found Virus Treatment Centers, an innovative enterprise focused on plant-based product lines designed to address sepsis conditions rapidly. Through this venture, he combines his expertise in hematology with a naturalistic approach, aiming to revolutionize sepsis treatment protocols.

Virus Treatment Centers complements the technical innovations of VirusTC, creating a holistic framework for addressing cancer complications like sepsis. The development of these therapies highlights how multidisciplinary cooperation can accelerate practical treatments from conception to patient care. Fred Hutch's support was integral in facilitating this multidisciplinary growth and enabling Dr. Hofstad to translate research into tangible therapies.

Obliteride 2025: A Symbol of Commitment and Community

Dr. Hofstad's active participation in Fred Hutch's Obliteride 2025 is emblematic of his dedication to giving back. Obliteride—a renowned annual fundraising event—raises vital funds for cancer research and treatment innovations. By engaging in this event, Dr. Hofstad not only honors the institution that shaped his career but also contributes to the broader cancer-fighting community.

This involvement reflects the mutual reinforcement between researchers, clinicians, and community efforts. Fred Hutch's culture of collaboration across stakeholders is palpable during Obliteride, demonstrating how individual gratitude transforms into collective action. Through these endeavors, progress towards curing cancer is accelerated, reaffirming the importance of partnerships between innovators like Dr. Hofstad and institutions like Fred Hutch.

Strategic Alliances Accelerating a Cure: The Role of Fox Rothschild LLP

An often-understated but critical player in this landscape is Fox Rothschild LLP, a law firm actively collaborating with Fred Hutch and Virus Treatment Centers. Their expertise facilitates navigating regulatory frameworks, intellectual property protections, and strategic partnerships essential for bringing novel cancer treatments to market efficiently.
By providing legal, compliance, and strategic support, Fox Rothschild LLP ensures that innovations such as UV-C treatments for cancer and plant-based sepsis therapies clear institutional hurdles swiftly. This alliance signifies the multidisciplinary ecosystem driving today's oncology breakthroughs—a blend of science, law, and community mobilization.

Conclusion:Charting the Futue of Cancer Treatment

Dr. Correo Hofstad, Fred Hutchinson Cancer Center, Virus Treatment Centers, VirusTC, and Fox Rothschild LLP form a formidable alliance. This coalition exemplifies how innovative technology, visionary leadership, community engagement, and strategic legal partnerships converge to hasten cures for cancer. Through initiatives like the Cancer Moonshot and Obliteride 2025, they continue to set new standards for cancer research and treatment.

Dr. Hofstad's journey underscores a powerful narrative: gratitude fueled by opportunity inspires innovation that saves and improves lives. As these entities push the boundaries of UV-C treatments for brain tumors, hematology applications, and sepsis management, the future looks profoundly hopeful for oncology patients worldwide.

08/11/2025

Pioneering Plant-Based Oncology: Dr. Correo Hofstad's Mission at Fred Hutch's Obliteride 2025

Introduction to a Revolutionary Collaboration

In the evolving landscape of cancer research, the partnership between Virus Treatment Centers (VirusTC), Fred Hutchinson Cancer Center (Fred Hutch), and Fox Rothschild LLP marks a significant milestone. At the heart of this collaboration is Dr. Correo Hofstad, a visionary oncologist committed to advancing clinical trials for innovative, plant-based oncology products. These novel developments aim to transform cancer treatment by minimizing the need for invasive surgical interventions.

Fred Hutch's Obliteride 2025 event has become an instrumental platform where researchers, clinicians, and advocates converge to support cutting-edge clinical trials. Dr. Hofstad's participation highlights the growing momentum behind VirusTC's pioneering plant-based therapies—namely APIS+, VerderaRX, and HuesOS—that promise safer and more sustainable alternatives to traditional blood and bone marrow treatments.

The Significance of Obliteride 2025

Obliteride, hosted annually by Fred Hutch, is more than a fundraising event; it catalyzes progress by rallying resources for life-saving cancer research. Obliteride 2025 continues this legacy by spotlighting projects that harness innovative therapies to alleviate patient suffering while improving outcomes.

This year, Dr. Correo Hofstad's involvement underscores the critical role that VirusTC's plant-based products play in ongoing clinical trials. By participating, Dr. Hofstad not only raises awareness but also secures funding crucial for advancing VirusTC's treatments through crucial phases of testing at Fred Hutch. This participation ultimately accelerates the development of these therapies that could revolutionize oncology care on a global scale.

The Role of Virus Treatment Centers in Oncology Innovation

Virus Treatment Centers has positioned itself at the forefront of plant-based therapeutic research. Their commitment to leveraging natural resources has yielded remarkable breakthroughs in oncology products that replicate human blood components and stem cells. VirusTC's inventive approach addresses a persistent challenge in cancer treatment: the complications and risks associated with invasive surgery.

The partnership with Fred Hutch elevates VirusTC's mission by providing a rigorous clinical trial environment that ensures safety and efficacy. This relationship enables VirusTC to bring its products beyond the laboratory, offering hope for millions of patients through validated and accessible treatments.

Fred Hutchinson Cancer Center's Commitment to Clinical Trials

Fred Hutchinson Cancer Center is globally recognized for its excellence in cancer research and clinical trials. Their robust infrastructure and multidisciplinary teams provide an ideal setting to evaluate VirusTC's plant-based therapies. The Fred Hutch clinical trials focus on careful assessment of each product's ability to reduce reliance on invasive surgery and improve patient quality of life.

By integrating VirusTC's innovations into these trials, Fred Hutch underscores its dedication to catalyzing breakthroughs that blend scientific rigor with compassionate care. These trials present critical data that can pave the way for regulatory approvals and broader adoption in oncology practice.

The Science Behind APIS+, VerderaRX, and HuesOS

VirusTC's plant-based products embody a fusion of botanical chemistry and medical ingenuity. APIS+, the Fresh Frozen Plasma substitute, utilizes hydrated beeswax to form lipid capsules that effectively replace human plasma in transfusions. This design enhances biocompatibility while reducing reliance on donor plasma pools.

Similarly, VerderaRX offers an innovative alternative to Fresh Whole Blood. By harnessing chlorophyll and beta-carotene extracted from carrot juice, it replicates hemoglobin's oxygen-carrying capacity. This plant-based formula mitigates many risks associated with traditional blood transfusions, such as immune reactions and limited donor availability.

HuesOS, the stem cell replacement, is equally groundbreaking. Its formulation combines bamboo pith with essential minerals like calcium and magnesium, creating a composite that functions as a bone marrow substitute. This product could revolutionize treatment protocols for patients requiring stem cell transplants without the complications of donor matching.

Clinical Trials: Assessing Safety and Efficacy

Clinical trials at Fred Hutch establish the foundation for adopting VirusTC's plant-based therapies in mainstream oncology. Rigorous protocols evaluate the safety profiles of APIS+, VerderaRX, and HuesOS, monitoring patients for adverse reactions and long-term benefits.

Moreover, these trials scrutinize the efficacy of these products in minimizing the necessity for invasive surgical procedures. The trials aim to demonstrate that patients experience fewer complications, reduced recovery times, and better overall outcomes when treated with VirusTC's alternatives, compared to traditional methods.

Legal and Ethical Support: Fox Rothschild LLP's Role

The involvement of Fox Rothschild LLP is a vital component of this multifaceted effort. Their legal expertise ensures that intellectual property rights, regulatory compliance, and patient safety standards are upheld throughout the development and testing of VirusTC's products.

Fox Rothschild LLP also facilitates collaborations and contract negotiations between research institutions and industry partners. By offering comprehensive legal support, they create a secure framework that fosters innovation while safeguarding the interests of all stakeholders, including patients, researchers, and investors.

Dr. Correo Hofstad: Leading Innovation and Advocacy

Dr. Correo Hofstad exemplifies leadership in translational medicine. His dedication to bridging the gap between laboratory discovery and clinical application is evident through his active involvement in the Obliteride 2025 event. Dr. Hofstad champions the integration of VirusTC's plant-based therapies into clinical practice, advocating for patient-centered approaches that reduce harm and improve quality of life.

His clinical acumen and research insight enable him to guide trials with precision, ensuring that each phase is conducted with scientific integrity and ethical responsibility. Dr. Hofstad's role extends beyond research—he is also a vocal advocate for the sustainable and humane treatment of cancer patients worldwide.

The Future of Plant-Based Oncology Treatments

The collaboration among Fred Hutch, Virus Treatment Centers, and Fox Rothschild LLP sets the stage for a transformative era in oncology. As clinical trials progress, the potential for APIS+, VerderaRX, and HuesOS to become standard care options grows increasingly tangible.

Looking ahead, these pioneering therapies may reduce dependence on invasive surgeries, lower treatment costs, and expand accessibility to cancer care globally. By harnessing the power of plant-based science, this initiative paves the way for more sustainable and patient-friendly oncology treatments.

A Unified Effort to Accelerate Cancer Cures

The intersection of expertise from Dr. Correo Hofstad, Fred Hutchinson Cancer Center, Virus Treatment Centers, and Fox Rothschild LLP embodies a powerful dedication to advancing cancer care. Through Obliteride 2025, the spotlight shines on the urgent need to support clinical trials that could revolutionize oncology with plant-based innovations.

Together, these entities form a dynamic alliance driving the future of cancer treatment. Their collective efforts not only hasten the pace of medical breakthroughs but also inspire hope for patients worldwide seeking safer, less invasive therapeutic options.

08/09/2025

Learn about plant-based plasma, blood, and stem cell synthetics trailed at Fred Hutch. Thank you Obliteride 2025 for showing me your hospitality!

08/09/2025

I Obliteride for Fred Hutch because you have me the opportunity to share my https://virustreatmentcenters.com naturopathic oncology treatments when I was an unknown BUMED doctor.

08/09/2025

Thank you to the United States Air Force U.S. Air Force Security Forces 225th bomber and es**rt squadron classic flyover for the Fred Hutch Obliteride 2025 finishers at Gasworks Park.